2020
DOI: 10.1016/j.reactfunctpolym.2020.104550
|View full text |Cite
|
Sign up to set email alerts
|

Biodegradable stent coatings on the basis of PLGA polymers of different molecular mass, sustaining a steady release of the thrombolityc enzyme streptokinase

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
11
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 26 publications
(13 citation statements)
references
References 47 publications
0
11
0
Order By: Relevance
“…Streptokinase-loaded PLGA membranes were successfully evaluated as coatings for nitinol stents, as they enabled a burst release of the antithrombotic agent after 3 days and its sustained slow release for 30 days. For a period of 60 days post-implantation, no allergic and immune reactions nor cardiac events were noticed [ 83 ].…”
Section: Resultsmentioning
confidence: 99%
“…Streptokinase-loaded PLGA membranes were successfully evaluated as coatings for nitinol stents, as they enabled a burst release of the antithrombotic agent after 3 days and its sustained slow release for 30 days. For a period of 60 days post-implantation, no allergic and immune reactions nor cardiac events were noticed [ 83 ].…”
Section: Resultsmentioning
confidence: 99%
“…Pharmaceutics, regardless of their molar weight, can be loaded into PLGA drug delivery systems and consequently released from the matrix in a controlled manner. Consequently, a wide variety of active compounds can be used as payload of PLGA based drug delivery systems ranging from small molecules such as anti-tumour drugs with molar weight 0.5 kDa [ 15 ] to proteins and enzymes with molar mass up to 50 kDa [ 16 , 17 ]. The drug release profile of PLGA based drug delivery systems is usually characterized by the initial burst of a loaded drug followed by zero order kinetics release [ 18 ].…”
Section: Introductionmentioning
confidence: 99%
“…Streptokinase was used to dissolve trapped microscopic clots in the trophoblastic and spongy layer of the amniochorionic membrane. Streptokinase is a thrombolytic enzyme that is used in the treatment of patients with pulmonary thromboembolism and myocardial infarctions 46 . Additionally, this fibrinolytic enzyme can also unbind cellular adhesions and help to decellularize the natural substrate 47 .…”
Section: Discussionmentioning
confidence: 99%